

Listing of the Claims:

Following is a complete listing of the claims in the application, as amended:

Claims 1-20 (Canceled)

21. (Previously Presented) A micellar suspension comprising a plurality of targeting conjugates for use in preparing a targeted, therapeutic liposome composition, each conjugate consisting essentially of (i) a lipid having a polar head group and a hydrophobic tail, (ii) a polyethylene glycol polymer having a proximal end and a distal end, said polymer attached at its proximal end to the head group of the lipid, and (iii) a targeting ligand having binding affinity for a receptor expressed on a cell attached to the distal end of the polymer.

22. (Previously Presented) The micellar suspension of claim 21, wherein the lipid is selected from the group consisting of distearoyl phosphatidylethanolamine, distearoyl-phosphatidylcholine, monogalactosyl diacylglycerols and digalactosyl diacylglycerols.

23. Cancelled

24. Cancelled

25. (Previously Presented) The micellar suspension of claim 24, wherein the polyethylene glycol has a molecular weight between 500-5,000 daltons.

26. (Previously Presented) The micellar suspension of claim 21, wherein the targeting ligand is an antibody or an antibody fragment.

27. (Previously Presented) The micellar suspension of claim 26, wherein the antibody or antibody fragment is a humanized murine antibody.

28. (Previously Presented) The micellar suspension of claim 21, wherein the targeting ligand specifically binds to an extracellular domain of a growth factor receptor.

29. (Previously Presented) The micellar suspension of claim 28, wherein the receptors are selected from the group consisting of c-erbB-2 protein product of the HER2/neu oncogene, epidermal growth factor receptor, basic fibroblast growth factor receptor and vascular endothelial growth factor receptor.

30. (Previously Presented) The micellar suspension of claim 21, wherein the targeting ligand binds a receptor selected from the group consisting of E-selectin receptor, L-selectin receptor, P-selectin receptor, folate receptor, CD4 receptor, CD19 receptor, $\alpha\beta$ integrin receptors and chemokine receptors.

31. (Previously Presented) The micellar suspension of claim 21, wherein the targeting ligand binds a receptor on a malignant B-cell or T-cell, said receptor selected from the group consisting of CD19, CD20, CD22, CD4, CD7 and CD8.

32. (Previously Presented) The micellar suspension of claim 21, wherein the targeting ligand is selected from the group consisting of folic acid, pyridoxal phosphate, vitamin B12, sialyl Lewis^x, transferrin, epidermal growth factor, basic fibroblast growth factor, vascular endothelial growth factor, VCAM-1, ICAM-1, PECAM-1, RGD peptides and NGR peptides.

Claims 33-56 (Canceled)

57. (Previously Presented) The micellar suspension of claim 21, wherein the targeting ligand is selected from the group consisting of water soluble vitamins, apolipoproteins, insulin, galactose, Mac-1, PECAM-1/CD31, fibronectin, osteopontin, RGD sequences of matrix proteins, HIV GP 120/41 domain peptomers, GP120 C4 domain peptomers, T cell tropic isolates, SDF-1 chemokines, Macrophage tropic

isolates, anti-cell surface receptor antibodies or fragments thereof, pyridoxyl ligands, biotin, RGD peptide mimetics, YIGSRG protein, $\alpha_v\beta_5$, IL-8, anti-E-selectin Fab.

58. (Previously Presented) The micellar suspension of claim 57, wherein the anti-cell surface receptor antibodies or fragments thereof is selected from the group consisting of anti-HER2/neu, anti-selectin and anti-VEGF pyridoxyl.

59. (Previously Presented) The micellar suspension of claim 57, wherein the pyridoxyl ligand is selected from the group consisting of pyridoxal, pyridoxine, pyridoxamine, pyridoxal 5'-phosphate and N-(4'-pyridoxyl)amines.

60-81. Cancelled